Villejuif

• EFRAIM II _ Empirical steroids and/or antifungals treatment of immunocompromised patients with acute respiratory failure of uknown origin: a … Ended
  2024-514344-82-00 5 2021-02-18 patients with acute respiratory failure from undetermined etiology
• Pembrolizumab + Lenvatinib for First Line Non-Clear Cell, Renal Cell Carcinoma Ended
  2023-504944-32-00 4 2021-02-17 Non-clear Cell Renal Cell Carcinoma
• A Phase 1 Study of TAS0612 in Patients with Locally Advanced or Metastatic Solid Tumors Ended
  2024-515175-35-00 1 2021-02-10 Locally Advanced or Metastatic Solid Tumors
• Study of DFF332 alone and in combination with Everolimus or Immuno-oncology therapies in patients with renal cell carcinoma and other select … Ended
  2024-513379-41-00 1 2021-01-26 Advanced, relapsed Clear Cell Renal Cell Carcinoma
• Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer (CERPASS) Ended
  2024-512652-38-00 4 2021-01-25 Cutaneous Squamous Cell Carcinoma
• A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inop … Ended
  2024-512331-72-00 5 2020-12-22 Squamous Carcinoma of the Anal Canal
• A phase I study evaluating safety and efficacy of Hepatic Intra- Arterial administration of ipilimumab in combination with Intra- venous niv … Ended
  2023-506156-25-00 9 2020-11-13 Advanced hepatocellular carcinoma
• A study to test Mirvetuximab Soravtansine (IMGN853) aganist doctor's choice of cancer medicines in women with advanced Epithelial Ovarian, P … Ended
  2024-516111-25-00 5 2020-11-09 Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Per
• A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cel … Ended
  2022-502480-38-00 5 2020-09-09 Non−small cell lung cancer (NSCLC)
• Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants with Melanoma (KEYMAK … Ended
  2023-506313-21-00 9 2020-08-03 PD-1 refractory melanoma
• Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melano … Ended
  2023-506314-51-00 9 2020-07-31 Stage IIIB or IIIC or IIID melanoma
• Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refracto … Ended
  2023-506312-41-00 9 2020-07-30 PD-1 refractory melanoma
• Clinical Trial of Lenvatinib, Pembrolizumab, and Standard Chemotherapy for Head and Neck Squamous Cell Carcinoma That has Returned or Spread Ended
  2022-500820-31-00 4 2020-07-16 Recurrent or metastatic squamous cell carcinoma of the head and neck
• A Study of Lenvatinib for Pediatric Patients with Relapsed or Refractory Solid Tumors Ended
  2024-512135-80-00 4 2020-07-13 Between ages 2 and 21 and have High Grade Glioma (HGG), Rhabdomyosarco
• A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (AcceleRET-Lung) Ended
  2023-505035-12-00 5 2020-06-12 RET fusion−positive, metastatic Non-Small Cell Lung Cancer
• Multicenter, Phase 3 Study of Venetoclax and Azacitidine as Maintenance Therapy for Patients with Acute Myeloid Leukemia in First Remission … Ended
  2023-507221-42-00 5 2020-06-03 Acute Myeloid Leukemia in First Remission
• Study that evaluating the efficacy of lenvatinib in patients with locally advanced GIST after failure of imatinib and sunitinib Ended
  2024-513984-22-00 4 2020-03-17 Patients with metastatic GIST
• A study to find out whether olaparib is safe and well tolerated when administered to children and adolescents Ended
  2023-507904-30-00 3 2020-01-27 solid tumors
• Olaparib Plus Pembrolizumab Compared to Chemotherapy Plus Pembrolizumab After Initial Treatment With Chemotherapy Plus Pembrolizumab in Trip … Ended
  2022-500418-24-00 10 2020-01-17 Locally Recurrent Inoperable or Metastatic Triple Negative Breast Canc
• Open-Label Study of Cabozantinib as 2nd Line Treatment in Subjects with Unresectable, Locally Advanced or Metastatic Renal Cell Carcinoma wi … Ended
  2024-514479-16-00 4 2019-10-28 Unresectable, Locally Advanced or Metastatic Renal Cell Carcinoma with
• Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects with Gastrointestinal, Pancreatic, or Colorectal Cancer Ended
  2023-507148-35-00 5 2019-10-03 Chemotherapy-induced Thrombocytopenia in Adult Subjects with Gastroint
• Pembrolizumab or Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced Ended
  2023-506657-38-00 5 2019-10-02 Biliary Tract Carcinoma
• Phase 3 Study of Pembrolizumab plus Enzalutamide in mCRPC Ended
  2022-500785-10-00 5 2019-08-23 Metastatic Castration-Resistant Prostate Cancer
• A Phase I First Time in Human Open Label Study of GSK3745417 Administered With and Without Anticancer Agents in Participants With Advanced S … Ended
  2024-513574-21-00 1 2019-08-09 Neoplasms

Showing 889–912 of 961 trials